Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $16.00 at Wedbush

Keros Therapeutics (NASDAQ:KROS) had its price objective lifted by Wedbush from $15.00 to $16.00 in a research report report published on Thursday,Benzinga reports. Wedbush currently has a neutral rating on the stock.

KROS has been the topic of a number of other research reports. Wells Fargo & Company started coverage on shares of Keros Therapeutics in a research report on Monday, October 20th. They set an “overweight” rating and a $26.00 target price on the stock. HC Wainwright dropped their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a research note on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.11.

Keros Therapeutics Stock Performance

Shares of KROS stock traded up $0.03 on Thursday, hitting $16.20. The company had a trading volume of 1,327,824 shares, compared to its average volume of 917,916. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37. The firm has a market cap of $493.61 million, a P/E ratio of 10.52, a P/E/G ratio of 2.02 and a beta of 1.12. The stock’s 50-day moving average is $15.48 and its two-hundred day moving average is $14.61.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.93. The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a return on equity of 9.63% and a net margin of 26.12%.The firm’s revenue was up 3585.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.41) earnings per share. Equities research analysts predict that Keros Therapeutics will post -4.74 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The SEC filing for this sale provides additional information. 20.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC raised its position in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after purchasing an additional 2,641 shares during the period. Tower Research Capital LLC TRC lifted its position in Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in Keros Therapeutics in the third quarter worth approximately $47,000. SG Americas Securities LLC bought a new position in Keros Therapeutics during the third quarter valued at approximately $103,000. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in shares of Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after acquiring an additional 1,892 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.